Search Results for: Clinical Roundup
-
Pharma: Clinic Roundup
Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, reported the first interim results in HCV/HIV co-infected patients from the company's ongoing hepatitis C (HCV) clinical trial program, HCVerso...Polyphor Ltd., of Allschwil, Switzerland, completed a Phase I trial demonstrating the clinical safety and tolerability of its Pseudomonas-specific antibiotic POL7080...The study compared the efficacy and safety of once-weekly Milprosa to daily 8 percentBioWorld Today | Tuesday, March 5, 2013 -
Ablynx Pads Cash Reserves to Push RA Drug into Phase IIb
In total, Ablynx has five products in clinical development and six in preclinical development, of which five are with partners...At the completion of the capital raising, Bionomics will have approximately $26 million in cash.By Nuala Moran | BioWorld Today | Tuesday, March 5, 2013 -
Financings Roundup
Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets...It also will support preparatory work to advance the firm's clinical-stage oncology program, DPX-Survivac, into Phase II development...It will use the proceeds to advance its opthalmic programs through clinical proof of conceptBioWorld Today | Friday, March 1, 2013 -
Pharma: Clinic Roundup
The volasertib clinical development program is the company's most advanced in cell cycle inhibitionBioWorld Today | Friday, March 1, 2013 -
Financings Roundup
Proceeds will be used to support continuing clinical development of Ravicti (glycerol phenylbutyrate) in HE, a brain disorder caused by chronic liver failureBioWorld Today | Thursday, February 28, 2013 -
Clinic Roundup
In conjunction with the changes in its clinical program, the company said it reduced its work force by 50 percent and outsourced noncritical research and development functionsBioWorld Today | Wednesday, February 27, 2013 -
$7M Series B Puts Investor Skin in Game for Brickell
The company is planning to begin clinical studies in the first half of 2014...The product, a therapeutic antibody, has shown potential in preclinical studies to to reduce damage, allowing pumping efficiency to return to normal levels.By Catherine Shaffer | BioWorld Today | Wednesday, February 27, 2013 -
Clinic Roundup
The study also has exploratory endpoints for clinical efficacy and inflammation biomarkers...Ltd., of Taipei, Taiwan, added two additional Taiwanese clinical centers in Cel-Sci's Phase III head and neck cancer trial for Multikine (Leukocyte Interleukin, Injection), including the China Medical University Hospital, of Taichung, Taiwan, and the Buddhist Tzu Chi General Hospital, of Hualian, TaiwanBioWorld Today | Tuesday, February 26, 2013 -
White House: Give the Public its Money's Worth
The agency also finalized its draft guidance on financial disclosures by clinical investigators...and explains the FDA's review of clinical investigator financial disclosure information.By Mari Serebrov | BioWorld Today | Tuesday, February 26, 2013 -
Pharma: Clinic Roundup
Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said pinoxacin hydrochloride received approval for clinical studies from the State Food and Drug AdministrationBioWorld Today | Monday, February 25, 2013 -
Immunomedics Seeks $14M as Bridge to Milestones
UCB also picked up clinical development and commercialization costs. (See BioWorld Today, May 11, 2006.) In 2009, the companies reported results from a Phase IIb dosing study of the drug showing a 24.9 percent treatment advantage over placebo in systemic lupus erythematosus (SLE) patients...The funding will support the advancement of Blaze's Tumor Paint product candidate, BLZ-100, into clinical development for use in surgery in multiple solid tumor types. (See BioWorld Today, June 11, 2012...OxygenBy Marie Powers | BioWorld Today | Monday, February 25, 2013 -
Clinic Roundup
The clinical trial is a randomized, double-blind, placebo-controlled parallel group study to evaluate the safety, clinical efficacy and pharmacokinetic profile of bertilimumab in subjects with active moderate-to-severe ulcerative colitis...Repros Therapeutics Inc., of The Woodlands, Texas, provided a clinical update of its Androxal Phase III program following receipt of written guidance from the FDABioWorld Today | Friday, February 22, 2013 -
Oncolytics Stock Offering Gets $32M to Push Reolysin
NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, is conducting four studies in various tumor types, which will "go a long way to helping us figure out" where to put the most resources, Look said...The multitude of clinical trials adds up to a program that "sounds like a heck of a burn requirement...The initial fundings position Cytomedix to execute on its 2013 operational business plan, the company said.By Randy Osborne | BioWorld Today | Thursday, February 21, 2013 -
Clinic Roundup
The primary objectives include the evaluation of adverse events and the evaluation of six-month clinical response...Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase II study, titled "Double-Blind, Placebo-Controlled Clinical Trial of EPI-743 in Patients with Cobalamin C DefectBioWorld Today | Wednesday, February 20, 2013 -
Clinic Roundup
Amicus Therapeutics Inc., of Cranbury, N.J., reported positive results from clinical and preclinical studies of the pharmacological chaperone AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease at the Lysosomal Disease Network World Symposium...Based on those results, the company plans to initiate a repeat-dose clinical study in the third quarter of 2013 to evaluate an intravenous formulation of AT2220 co-administered with Myozyme/Lumizyme...The company is currently enrolling patientsBioWorld Today | Friday, February 15, 2013 -
Petition to Delay Biosimilar Game in U.S. Picks up Steam
and reduced preclinical and clinical head-to-head comparability studies...Sponsors may change the host cell type for a biosimilar only if they provide data proving that the structure of the biologic is not affected and that the clinical profile will not change...Editor's note: For a copy of BioWorld's new biosimilars report, please contact the BioWorld Data account managers for exclusive introductory pricing at (800) 477-6307.By Mari Serebrov | BioWorld Today | Friday, February 15, 2013 -
Regeneron Earnings Driven by Strong Sales of Eylea
Jonathan Aschoff, of Brean Capital LLC, noted that his company had previously downgraded Regeneron shares to Hold due to a concern that the mid-2013 clinical data would be a "significant potential negative catalyst...The company reported a net loss of $0.5 million, or $0.03 per share, for 2012, compared to net income of $9.7 million, or $0.49, for 2011.By Catherine Shaffer | BioWorld Today | Friday, February 15, 2013 -
Clinic Roundup
PROSTVAC and MVA-BN PRO, will be the subject of clinical presentations at the 2013 Genitourinary Cancers Symposium on Feb. 14-16, in Orlando, Fla...Two posters feature clinical data of PROSTVAC evaluated as monotherapy or in combination with a radiopharmaceutical...The preliminary results from the studies supported the further clinical investigation in patients suffering from advanced prostate cancer, the company saidBioWorld Today | Thursday, February 14, 2013 -
Pharma: Clinic Roundup
The data, from the latest pre-specified interim analysis of the study, were presented at the annual American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando, FlaBioWorld Today | Thursday, February 14, 2013 -
OIG: Who Knows Whether REMS Improve Drug Safety?
actions the FDA can take to mitigate the negative impact a shortage may have on research and clinical trials...Comments are due by March 14.By Mari Serebrov | BioWorld Today | Thursday, February 14, 2013
Category
Related Keywords
Categories
- x BioWorld Today (2577)
- x BioWorld International (51)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.